- About Progeria
- About PRF
- Meet the Kids
- Medical Research
- Parents & Doctors
- Get Involved
- Fundraising Events
- Contact Us
- Donate Now
The Progeria Research Foundation has brought Progeria to the forefront of research efforts, engaging large, reputable institutions such as the National Institutes of Health (NIH) and Children’s Hospital Boston (CHB) to invest their resources in Hutchinson-Gilford Progeria Syndrome. NIH has co-sponsored 7 scientific workshops with PRF, CHB is a partner in the first-ever Progeria Clinical Drug Trials.
April 2015: PRF encourages proposals in the areas listed below. Investigators are not limited to applications that address these priorities, but rather are encouraged to use them to better understand the needs of the field at this time.
PRF is seeking proposals that address the following priorities:
Discovery of biological markers of disease in HGPS that can be assessed in human and/or mouse samples. Highest priority will be given to those markers that can be assayed in easily obtainable human samples such as blood, urine, and cheek swabs. In addition, proposals that explore biomarker relevance to disease process and /or change in markers with disease treatment are encouraged.
Discovery and/or testing of candidate treatment compounds in both cell based and mouse models of HGPS. Of note, proposals should test compounds in a progerin-producing mouse model as the priority. Comparisons to other mouse models of disease, such as ZMPSTE24 -/- and other non-progerin producing mouse models is acceptable, but only as a comparison to progerin-producing models.
September 2011: PRF Announces New Granting Structure
Since its inception in 1999, PRF had awarded grants to investigators at a maximum of $50,000 per year for up to two years. The funding was intended to allow researchers to produce enough preliminary data to be competitive for greater, longer-term funding by NIH or other large agencies. PRF's Grant Program served Progeria research very well, yielding major advances that have propelled Progeria from a disease about which virtually nothing was known at the cellular and molecular levels, to one that was understood well enough to begin clinical drug trials.
In September 2011, PRF's Medical Research Committee devised a new granting structure. Proposals are now accepted in three categories of differing type, funding levels, and length of time:
a. The Principal Investigator demonstrate substantial progress and commitment to the field, for example by applying for at least one major grant to continue Progeria work. Examples of major grants include NIH RO1 or Ellison Senior Scholar funding.
b. The Principal Investigator has submitted a manuscript on the Progeria work accomplished in the first two years.
Grants are considered twice per year, usually at the Board of Directors' June and December meetings, with applications due eight weeks prior.
Grant Applications are due:
April 20, 2015*
*Grant Application deadlines are subject to change. Please email us or check back on this site periodically for the most up-to-date information.
Are you looking to enter the field of Progeria research?
Please note that The Progeria Research Foundation does not directly conduct research projects. Rather, we fund some of the research, which takes place at various institutions and hospitals around the world. Thus we have no control over the personnel involved in this work, including interns, post-docs, etc. However, on our website you will find links to those PRF is currently funding at our Grants Funded page and you are welcome to contact them directly to inquire as to whether or not a position is available. In addition, we suggest you review the published scientific papers that many scientists have written at our Scientific Publications and Whats New in Progeria Research pages. Perhaps you can contact some of these researchers to inquire about a position in their labs.
Best of luck with your search, and we hope you DO end up working in this fascinating field!